Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing.
A case to illustrate the utility of genetic screening in warfarin (Coumadin) management is reported. A 45 year-old woman of Puerto Rican ancestry was admitted to the emergency room twice within one month with chest pain. She was diagnosed with congestive heart failure, which was stabilized both times. At her second release, warfarin therapy was initiated at 5 mg/ day to prevent thrombus formation and was lowered to 3.75 mg/day at day 7 by her primary physician. International Normalized Ratio (INR) test results in the follow-up period at days 1, 7, and 10 of warfarin therapy were 4.5, 6.5, and 7.3, respectively-far in excess of the therapeutic range, despite the lower dosage in effect from day 7 onward. The patient achieved target INR over the next 43 days after downward adjustment of the dose to a dose of 1.5 mg/day by trial and error. DNA-typing specific for the CYP2C9*2,*3,*4,*5,*6 alleles and seven variants in the VKORC1 gene, including the VKORC1-1639 G > A polymorphism, revealed the presence of combinatorial CYP2C9*2/*3 and VKORC1-1639 G/A genotypes in this patient. Entering the patient's demographic and genotype status data into independent algorithms available in the public domain to predict effective warfarin dose yielded predicted doses which ranged from 1.5 to 1.8 mg/day. Notably, the prediction of 1.5 mg/day, which was generated by the online resource www.warfarindosing.org, coincided with the patient's actual effective warfarin dose. We conclude that the rapid rise in INR observed upon the initiation of warfarin therapy and the final effective warfarin dose of 1.5 mg/day, are attributable in some part to the presence of two minor alleles in CYP2C9, which together significantly reduce warfarin metabolism. Warfarin genotyping can therefore inform the clinician of the predicted effective warfarin dose. The results highlight the potential for warfarin genetic testing to improve patient care.
University of Puerto Rico School of Pharmacy, San Juan Puerto Rico.
Rosángela
R
Rodríguez-Vélez
Oscar J
OJ
Ortiz-Rivera
Bruce
B
Bower
Krystyna
K
Gorowski
Andreas
A
Windemuth
David
D
Villagra
Mohan
M
Kocherla
Richard L
RL
Seip
Darrin
D
D'Agostino
Cunegundo
C
Vergara
Gualberto
G
Ruaño
Jorge
J
Duconge
D000925:Anticoagulants / Q000008:administration & dosage*; D005260:Female; D005838:Genotype; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D019934:International Normalized Ratio; D008875:Middle Aged; D012307:Risk Factors; D014859:Warfarin / Q000008:administration & dosage*
D000925:Anticoagulants; D014859:Warfarin
Clin Pharmacol Ther. 2002 Dec;72(6):702-10
12496751
Am J Cardiol. 2005 Aug 15;96(4):595-8
16098319
Am Heart J. 2005 Apr;149(4):650-6
15990748
Per Med. 2008 May;5(3):225-232
29783498
Thromb Haemost. 2004 Jun;91(6):1123-8
15175798
Thromb Haemost. 2005 Apr;93(4):700-5
15841315
JAMA. 2002 Apr 3;287(13):1690-8
11926893
N Engl J Med. 2009 Feb 19;360(8):753-64
19228618
Clin Med Res. 2005 Aug;3(3):137-45
16160068
Clin Pharmacol Ther. 2008 Feb;83(2):312-21
17653141
N Engl J Med. 2008 Mar 6;358(10):999-1008
18322281
Clin Pharmacol Ther. 2006 Jul;80(1):13-22
16815313
Ethn Dis. 2009 Autumn;19(4):390-5
20073138
Pharmacogenomics. 2008 Feb;9(2):169-78
18370846
Am Fam Physician. 1999 Feb 1;59(3):635-46
10029789
J Thromb Thrombolysis. 2002 Dec;14(3):227-32
12913403
Ann Intern Med. 2003 Dec 2;139(11):893-900
14644891
Thromb Haemost. 2000 Nov;84(5):775-8
11127854
Hum Genet. 2007 Mar;121(1):23-34
17048007
Clin Pharmacol Ther. 2008 Dec;84(6):722-8
18754001
JAMA. 2006 Oct 18;296(15):1858-66
17047216
Blood. 2005 Oct 1;106(7):2329-33
15947090
Am J Health Syst Pharm. 2009 Jan 15;66(2):123-33
19139476
Clin Med Res. 2007 Mar;5(1):8-16
17456829
Br J Clin Pharmacol. 2006 Jun;61(6):746-51
16722840
Per Med. 2007 Feb;4(1):11-31
29793302
Pharmacogenetics. 2004 Aug;14(8):539-47
15284536
Arch Intern Med. 1993 Jul 12;153(13):1557-62
8323419
Ann Intern Med. 2009 Jan 20;150(2):73-83
19153410
N Engl J Med. 2005 Jun 2;352(22):2285-93
15930419
Clin Chem. 2007 Jul;53(7):1199-205
17510308
Blood. 2000 Sep 1;96(5):1816-9
10961881
Pharmacogenomics. 2009 Apr;10(4):565-77
19374515